Inferra AI / Company / GRDN
Guardian Pharmacy Services, Inc.
GRDN · Consumer Discretionary
Last earnings Aug 6, 2026
Key results
Revenuequarter
$344.3 million
Second Quarter Financial Results Revenue of $344.3 million, up 15% year-over-year, driven by low double-digit organic growth and acquisitions completed over the past 12 months.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Growthquarter
up 15%
Second Quarter Financial Results Revenue of $344.3 million, up 15% year-over-year, driven by low double-digit organic growth and acquisitions completed over the past 12 months.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Net incomequarter
$8.8 million
Net Income of $8.8 million, compared to $15.8 million in the prior-year period.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
EPSquarter
$0.14
Diluted EPS of $0.14 for the quarter, with Adjusted EPS 3 of $0.23.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
AI analysis
Q2 2025 · reported Aug 11, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $344.3 million | — | — |
| Growth | up 15% | — | — |
| Net income | $8.8 million | — | $15.8 million |
| EPS | $0.14 | — | — |
Guidance · company-stated
Direction: Raised
“htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2025 Financial Results; Raises Full-Year Guidance ATLANTA, August 11, 2025 Guardian Pharmacy Services, Inc.”
“In light of our performance through the first half of 2025, we re raising our full-year guidance across both revenue and adjusted EBITDA.”
“FY 2025 Outlook Raising Guidance The updated guidance below excludes future acquisitions or greenfield expansions.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Cash and cash equivalents totaled $18.8 million at quarter-end, with no long-term debt outstanding under our credit facility.
, against cyber-attacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense; and volatility of our stock price.
Event summary
Guardian Pharmacy Services Reports Second Quarter 2025 Financial Results; Raises Full-Year Guidance
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Company outlook — Raised (“Raises”)
“htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2025 Financial Results; Raises Full-Year Guidance ATLANTA, August 11, 2025 Guardian Pharmacy Services, Inc.”
Revenue — Raised (“raising”)
“In light of our performance through the first half of 2025, we re raising our full-year guidance across both revenue and adjusted EBITDA.”
Company outlook — Raised (“Raising”)
“FY 2025 Outlook Raising Guidance The updated guidance below excludes future acquisitions or greenfield expansions.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Cash and cash equivalents totaled $18.8 million at quarter-end, with no long-term debt outstanding under our credit facility.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
, against cyber-attacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense; and volatility of our stock price.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
, against cyber-attacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; and the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense.
SEC original ↗Guardian Pharmacy Services, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
Combined with our clear growth strategy and the enhanced float from our recent secondary offering, we believe Guardian is well-positioned to deliver long-term value for shareholders as we remain a strong leader in the ALF segment of LTC pharmacies.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Operational and Strategic Highlights Acquisitions & Greenfields During the quarter, Guardian expanded its national presence with the addition of two new pharmacies located in attractive growth markets: Wichita, KS (April) and Seattle, WA (June).
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Acquisitions The Company s growth strategy involves periodically acquiring institutional pharmacies servicing LTCFs and their residents as well as residents in other care settings.
SEC original ↗Guardian Pharmacy Services, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company s strategy includes the acquisition of freestanding institutional pharmacy businesses as well as other assets, generally less significant in size, which are combined with existing pharmacy operations to augment internal organic growth.
SEC original ↗Guardian Pharmacy Services, Inc. — 10-Q Quarterly report10-QAug 6, 2026
In addition to comparing net income against forecasted net income, the CODM uses net income to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits into the operating segment or expansion of the operating segment through acquisitions.
SEC original ↗Guardian Pharmacy Services, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, many of which are beyond our control.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
We are subject to additional risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission from time to time, including in the Risk Factors section contained in our most recent Annual Report on Form 10-K, which report is publicly available at www.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
(2) Represents non-recurring attorney s fees, settlement costs and other expenses associated with certain legal proceedings.
SEC original ↗Guardian Pharmacy Services, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Legal Proceedings 30 ITEM 1A.
SEC original ↗Guardian Pharmacy Services, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, some of which are beyond our control.
SEC original ↗Guardian Pharmacy Services, Inc. — 10-Q Quarterly report10-QAug 6, 2026
For more information regarding these risks and uncertainties, as well as certain additional risks that we face, refer to Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025 and the factors more fully described in Management s Discussion and Analysis of Financial Condition and Results of Operations in this Quarterly Report on Form 10-Q.
SEC original ↗Guardian Pharmacy Services, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Earnings deck slides
0 decks with slide viewGuardian Pharmacy Services, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Guardian Pharmacy Services, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Guardian Pharmacy Services, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Guardian Pharmacy Services, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documentsEarnings releases
9 documentsPresentations
4 documents
Transcripts
0 documentsNo transcripts for Guardian Pharmacy Services, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.